RxDoctor Payments Data

Jessica Swarr, PA

Physician Assistant · Dayton, OHNPI 1548498652

Payments from drug & device makers

$9,955in general payments, 2019–2025

Across 554 payments — averaging $17.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Alkermes, Inc.$1K
  • Lundbeck LLC$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • Teva Pharmaceuticals USA, Inc.$974
  • Otsuka America Pharmaceutical, Inc.$901
  • plus $3K from 13 others

What the payments were for

  • Food & beverage$9,83899%
  • Education$1171%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,955 in reported general payments places this provider in the 95th percentile of 4,098 physician assistant providers in Ohio.

See all physician assistant providers in Ohio

Medicare billing

Part B allowed, 2024
$50,792
Medicare patients
72
Services billed
739

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate17$140,945
RexultiBrexpiprazole27$45,414
VraylarCariprazine Hcl24$33,404
CaplytaLumateperone Tosylate16$32,202
Aripiprazole252$17,803
Olanzapine117$2,834
Bupropion XlBupropion Hcl128$2,252
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine38$2,047
Fluvoxamine Maleate29$1,977
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine42$1,677
Quetiapine Fumarate141$1,652
Naltrexone Hcl25$1,356
Buspirone Hcl59$1,261
Venlafaxine Hcl ErVenlafaxine Hcl93$1,231
Duloxetine Hcl78$1,145

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$503$140,94517 claims
Otsuka America Pharmaceutical, Inc.Rexulti$901$45,41427 claims
AbbVieVraylar$1,282$33,40424 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$1,086$32,20216 claims
Almatica Pharma LLCSertraline Hcl$49$61264 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,098 physician assistant providers in Ohio.

Other physician assistant in Dayton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →